Effect of Topiroxostat on Urinary Albumin in hyperuricemic patients with Diabetic nephropathy
- Conditions
- Diabetic nephropathy with hyperuricemia
- Registration Number
- JPRN-UMIN000015403
- Lead Sponsor
- Department of Nephrology, Nagoya University Graduate School of Medicine
- Brief Summary
The changes in UACR after 24 weeks of treatment (or at the final time point if patients failed to reach 24 weeks) relative to the baseline were -122 mg/gCr (95% CI: -5.1 to -240.1, P = 0.041) in patients treated with high dose, while treatment with low dose topiroxostat could not show significant reduction (P = 0.067).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Not provided
1 Poor diabetic control 2 Patient have been treated with steroids 3 Patient with nephropathy excluding diabetic nephropathy (including: nephrosclerosis) 4 Cancer 5 Systemic disease with proteinuria (collagen disease, vasculitis and amyloidosis) 6 Gouty arthritis within 6 months 7 ALT, AST >= double as the standard of each hospital 8 Active Hepatitis C and/or C 9 Liver cirrhosis 10 Patients are deemed unsuitable by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method